Chinese Medical Sciences Journal ›› 2015, Vol. 30 ›› Issue (3): 170-173.doi: 10.1016/S1001-9294(15)30042-0

• 论著 • 上一篇    下一篇

Cerebrospinal Fluid Biomarkers in Dementia Patients with Cerebral Amyloid Angiopathy

Yan-feng Li1, Fang-fang Ge, Yong Zhang1, Hui You2, Zhen-xin Zhang1,*   

  1. 1 Department of Neurology,;
    2 Department of Radiology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China
  • 出版日期:2015-10-02 发布日期:2015-10-02

Cerebrospinal Fluid Biomarkers in Dementia Patients with Cerebral Amyloid Angiopathy

Yan-feng Li1, Fang-fang Ge, Yong Zhang1, Hui You2, Zhen-xin Zhang1,*   

  1. 1 Department of Neurology,;
    2 Department of Radiology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China
  • Published:2015-10-02 Online:2015-10-02

摘要: Objective To study the changes of biomarkers in cerebrospinal fluid (CSF) in cerebral amyloid angiopathy (CAA) dementia and Alzheimers disease.Methods Levels of amyloid protein β (Aβ42, Aβ40) and phosphorylated Tau-protein (P-tau) in CSF and ratio of Aβ42/Aβ40 were tested in 5 cases with CAA dementia and 20 cases with Alzheimer’s disease collected at Peking Union Medical College Hospital from December 2001 to March 2011.Results The levels of Aβ42, Aβ40, and P-tau in CSF and ratio of Aβ42/Aβ40 were (660.4±265.2) ng/L, (7111.0±1033.4) ng/L, (71.8±51.5) ng/L, and 0.077±0.033, respectively in CAA dementia and (663.6±365.6) ng/L, (5115.0±2931.1) ng/L, (47.7±38.8) ng/L, and 0.192±0.140, respectively in Alzheimer’s disease patients. There were no statistically significant differences between CAA dementia and Alzheimer’s disease in terms of these CSF biomarkers (all P>0.05).Conclusion Measurements of CSF biomarkers may not be helpful in differential diagnosis of CAA and Alzheimer’s disease.

关键词: cerebral amyloid angiopathy, Alzheimer’, s disease, cerebrospinal fluid biomarker

Abstract: Objective To study the changes of biomarkers in cerebrospinal fluid (CSF) in cerebral amyloid angiopathy (CAA) dementia and Alzheimers disease.Methods Levels of amyloid protein β (Aβ42, Aβ40) and phosphorylated Tau-protein (P-tau) in CSF and ratio of Aβ42/Aβ40 were tested in 5 cases with CAA dementia and 20 cases with Alzheimer’s disease collected at Peking Union Medical College Hospital from December 2001 to March 2011.Results The levels of Aβ42, Aβ40, and P-tau in CSF and ratio of Aβ42/Aβ40 were (660.4±265.2) ng/L, (7111.0±1033.4) ng/L, (71.8±51.5) ng/L, and 0.077±0.033, respectively in CAA dementia and (663.6±365.6) ng/L, (5115.0±2931.1) ng/L, (47.7±38.8) ng/L, and 0.192±0.140, respectively in Alzheimer’s disease patients. There were no statistically significant differences between CAA dementia and Alzheimer’s disease in terms of these CSF biomarkers (all P>0.05).Conclusion Measurements of CSF biomarkers may not be helpful in differential diagnosis of CAA and Alzheimer’s disease.

Key words: cerebral amyloid angiopathy, Alzheimer’s disease, cerebrospinal fluid biomarker

Copyright © 2018 Chinese Academy of Medical Sciences. All right reserved.
 
www.cmsj.cams.cn
京公安备110402430088 京ICP备06002729号-1  Powered by Magtech.

Supervised by National Health Commission of the People's Republic of China

9 Dongdan Santiao, Dongcheng district, Beijing, 100730 China

Tel: 86-10-65105897  Fax:86-10-65133074 

E-mail: cmsj@cams.cn  www.cmsj.cams.cn

Copyright © 2018 Chinese Academy of Medical Sciences

All right reserved.

京公安备110402430088  京ICP备06002729号-1